These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15640825)

  • 1. Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis.
    Thaunat O; Alyanakian MA; Varnous S; Bors V; Damaj G; Rerolle JP; Jondeau K; Varet B; Gandjbakhch I; Buzyn A
    Bone Marrow Transplant; 2005 Feb; 35(4):419-20. PubMed ID: 15640825
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis.
    Sack FU; Kristen A; Goldschmidt H; Schnabel PA; Dengler T; Koch A; Karck M
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):257-62. PubMed ID: 18096396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone marrow transplantation in AL amyloidosis?].
    Winter EF
    Dtsch Med Wochenschr; 1991 Aug; 116(35):1334. PubMed ID: 1879331
    [No Abstract]   [Full Text] [Related]  

  • 4. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can autologous bone marrow transplantation improve systolic function in patients with multiple myeloma related cardiac amyloidosis?
    Raina S; Pant S; Vallurupalli S; Jambhekar K; Pandey T; Grazziutti M; Barlogie B; Dai Y; Deshmukh A; Mehta JL
    Int J Cardiol; 2014 Mar; 172(1):265-6. PubMed ID: 24456883
    [No Abstract]   [Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation for systemic AL amyloidosis.
    Gillmore JD; Davies J; Iqbal A; Madhoo S; Russell NH; Hawkins PN
    Br J Haematol; 1998 Jan; 100(1):226-8. PubMed ID: 9450816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.
    Maurer MS; Raina A; Hesdorffer C; Bijou R; Colombo P; Deng M; Drusin R; Haythe J; Horn E; Lee SH; Marboe C; Naka Y; Schulman L; Scully B; Shapiro P; Prager K; Radhakrishnan J; Restaino S; Mancini D
    Transplantation; 2007 Mar; 83(5):539-45. PubMed ID: 17353770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
    Sanchorawala V; Seldin DC; Magnani B; Skinner M; Wright DG
    Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac amyloidosis - experience in a tertiary cardiac referral centre.
    Chau EM; Chow WH; Wang E; Kwong YL
    Int J Cardiol; 2008 Feb; 124(2):264-6. PubMed ID: 17383027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term donor-specific tolerance in rat cardiac allografts by intrabone marrow injection of donor bone marrow cells.
    Guo K; Inaba M; Li M; An J; Cui W; Song C; Wang J; Cui Y; Sakaguchi Y; Tsuda M; Omae M; Ando Y; Li Q; Wang X; Feng W; Ikehara S
    Transplantation; 2008 Jan; 85(1):93-101. PubMed ID: 18192918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early pediatric anthracycline cardiotoxicity: managed by serial heart and bone marrow transplantation.
    Mangat JS; Rao K; Kingston J; Veys P; Amrolia P; Burch M
    J Heart Lung Transplant; 2007 Jun; 26(6):658-60. PubMed ID: 17543795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantation of a cardioverter-defibrillator in a patient with cardiac amyloidosis.
    Wright BL; Grace AA; Goodman HJ
    Nat Clin Pract Cardiovasc Med; 2006 Feb; 3(2):110-4; quiz 115. PubMed ID: 16446780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
    Palladini G; Russo P; Lavatelli F; Nuvolone M; Albertini R; Bosoni T; Perfetti V; Obici L; Perlini S; Moratti R; Merlini G
    Ann Hematol; 2009 Apr; 88(4):347-50. PubMed ID: 18779964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes.
    Sanchorawala V; Blanchard E; Seldin DC; O'Hara C; Skinner M; Wright DG
    Am J Hematol; 2006 Sep; 81(9):692-5. PubMed ID: 16795060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.